Churn churn churn, page-17

With Epidiolex being FDA approved and sharing cannabidiol as the driving substance, there's plenty of reason to be confident. The base product isn't steroid driven which I'd say a very high percentage of those failing stats would be.

The results to date are virtually flawless, so I'd say it's using the product for an extended period of time which could be the only reason we get let down.. however CBD in Epidiolex clearly shows that aspect causes no concern.

Also, phase 2 is about the efficacy, and if we look at the acne treatment on it's own, it was already 5% ahead on reduced lesions than the current leading approved product after just 28 days.

I think originally for BOT funds were the concern, but being cashed up for 2 phase 2 trials will see buyers come in due course. We're just feeling from the CR at this stage but with all things considered, IMO, BOT is ridiculously dirt cheap at the moment.

All IMO of course